Calliditas Therapeutics

NASDAQ CALT

Data sourced from

and

Download Data

Calliditas Therapeutics Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2024: 6.40%

Calliditas Therapeutics Pre-Tax Margin is 6.40% for the Trailing 12 Months (TTM) ending March 31, 2024, a 108.38% change year over year. Pre-tax margin represents the proportion of a company's earnings before taxes (EBT) to its revenue. It is calculated by dividing the EBT by the revenue. This ratio indicates the profitability of the company's operations before the impact of taxes. A higher pre-tax margin suggests that the company generates a larger proportion of revenue as pre-tax profit, indicating stronger operational performance and efficiency.

Calliditas Therapeutics Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -76.38%, a 84.10% change year over year.
Calliditas Therapeutics Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -480.39%, a 98.81% change year over year.
Calliditas Therapeutics Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -40,506.75%, a -806.13% change year over year.
Calliditas Therapeutics Pre-Tax Margin for the Trailing 12 Months (TTM) ending March 31, 2020 was -4,470.31%.

NASDAQ: CALT

Calliditas Therapeutics

CEO	Ms. Renee Aguiar-Lucander
IPO Date	June 5, 2020
Location	Sweden
Headquarters	Kungsbron 1, D5, Stockholm, Sweden, 111 22
Employees	217
Sector	Healthcare
Industry	Biotechnology

Description

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Key trends